AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Peripherally-Acting Cannabinoid Receptor Agonists for Chronic Pain

Technology Benefits: No centrally-mediated side effectsHigh affinity for cannabinoid receptors

Technology Application: Control chronic pain of inflammatory and neuropathic originReduce intraocular pressure

Detailed Technology Description: Dr. Igor Spigelman of UCLA’s School of Dentistry and Dr. Herbert Seltzman, a collaborator at RTI International, have designed small molecules effective in alleviating chronic pain of inflammatory and neuropathic origin without any centrally-mediated side effects. The molecules are peripherally-acting cannabinoid compounds with high affinity for cannabinoid receptors and have been specifically designed to have limited permeability at the blood-brain barrier.

Application No.: 9656981

Others

State Of Development

Compounds with high agonist activity for CB₁R and low BBB permeability were examined for stability in blood plasma
Pharmacokinetic studies support minimal brain penetration
Preclinical trials in rat models of chronic inflammatory and neuropathic pain have been completed and lead compounds have been identified

Background

Current treatments of different types of chronic pain are geared towards decreasing inflammation (if it exists) and maximizing pain relief while minimizing side effects associated with each particular drug type. Unfortunately, this has been a difficult goal to achieve and all of the current treatments for chronic pain, particularly pain of neuropathic origin, have significant side effects which limit their usefulness. Recently, drugs targeting cannabinoid receptors have proven efficacious for patients. However, while current clinical treatments with FDA-approved cannabinoid-based analgesic can provide relief from chronic pain symptoms, these treatments also produce several significant central nervous system-mediated side effects.

Tech ID/UC Case

23480/2012-715-0

Related Cases

2012-715-0

*Abstract: Researchers from UCLA and RTI International have developed novel, small molecule agonists at cannabinoid type 1 and type 2 receptors (CB1R and CB2R) that have low blood-brain barrier (BBB) permeability. The compounds represent promising therapeutics for treating chronic pain.

*IP Issue Date: May 23, 2017

*Principal Investigator: Name: Herbert Seltzman
Department:

Name: Craig Shiner
Department:

Name: Igor Spigelman
Department:

Country/Region: USA

For more information, please click Here